Treatment of Neuromyelitis Optica Spectrum Disorder: Acute, Preventive, and Symptomatic
- PMID: 26705758
- PMCID: PMC4807395
- DOI: 10.1007/s11940-015-0387-9
Treatment of Neuromyelitis Optica Spectrum Disorder: Acute, Preventive, and Symptomatic
Abstract
Neuromyelitis optica spectrum disorder (NMOSD) is a rare, autoimmune disease of the central nervous system that primarily attacks the optic nerves and spinal cord leading to blindness and paralysis. The spectrum of the disease has expanded based on the specificity of the autoimmune response to the aquaporin-4 water channel on astrocytes. With wider recognition of NMOSD, a standard of care for treatment of this condition has condition based on a growing series of retrospective and prospective studies. This review covers the present state of the field in the treatment of acute relapses, preventive approaches, and therapies for symptoms of NMOSD.
Keywords: Azathioprine; Eculizumab; Immunosuppression; Mycophenolate; Neuromyelitis optica spectrum disorder; Rituximab.
Conflict of interest statement
Similar articles
-
New therapies for neuromyelitis optica spectrum disorder.Lancet Neurol. 2021 Jan;20(1):60-67. doi: 10.1016/S1474-4422(20)30392-6. Epub 2020 Nov 10. Lancet Neurol. 2021. PMID: 33186537 Review.
-
Neuromyelitis Optica Spectrum Disorder: Clinical Burden and Cost of Relapses and Disease-Related Care in US Clinical Practice.Neurol Ther. 2021 Dec;10(2):767-783. doi: 10.1007/s40120-021-00253-4. Epub 2021 May 27. Neurol Ther. 2021. PMID: 34046846 Free PMC article.
-
Present and Future Therapies in Neuromyelitis Optica Spectrum Disorders.Neurotherapeutics. 2016 Jan;13(1):70-83. doi: 10.1007/s13311-015-0400-8. Neurotherapeutics. 2016. PMID: 26597098 Free PMC article. Review.
-
Efficacy and tolerability of azathioprine for neuromyelitis optica spectrum disorder: A systematic review and meta-analysis.Mult Scler Relat Disord. 2019 Aug;33:22-32. doi: 10.1016/j.msard.2019.05.011. Epub 2019 May 22. Mult Scler Relat Disord. 2019. PMID: 31136907
-
What's new in neuromyelitis optica spectrum disorder treatment?Taiwan J Ophthalmol. 2022 Sep 1;12(3):249-263. doi: 10.4103/2211-5056.355617. eCollection 2022 Jul-Sep. Taiwan J Ophthalmol. 2022. PMID: 36248092 Free PMC article. Review.
Cited by
-
Neuromyelitis Optica: A Deceiving Disorder of Demyelination.Cureus. 2024 Jul 22;16(7):e65123. doi: 10.7759/cureus.65123. eCollection 2024 Jul. Cureus. 2024. PMID: 39171010 Free PMC article.
-
Use of Complementary and Alternative Medicine in Patients With Idiopathic Inflammatory Demyelinating Diseases of the Central Nervous System: A Cross-Sectional Study in Thailand.Curr Ther Res Clin Exp. 2024 Apr 25;100:100749. doi: 10.1016/j.curtheres.2024.100749. eCollection 2024. Curr Ther Res Clin Exp. 2024. PMID: 38808155 Free PMC article.
-
Successful Childbirth During Satralizumab Treatment in Neuromyelitis Optica Spectrum Disorder.Cureus. 2024 Feb 27;16(2):e55010. doi: 10.7759/cureus.55010. eCollection 2024 Feb. Cureus. 2024. PMID: 38550492 Free PMC article.
-
Therapeutic inertia in the management of neuromyelitis optica spectrum disorder.Front Neurol. 2024 Feb 21;15:1341473. doi: 10.3389/fneur.2024.1341473. eCollection 2024. Front Neurol. 2024. PMID: 38450077 Free PMC article.
-
A single relapse induces worsening of disability and health-related quality of life in patients with neuromyelitis optica spectrum disorder.Front Neurol. 2023 Apr 11;14:1099376. doi: 10.3389/fneur.2023.1099376. eCollection 2023. Front Neurol. 2023. PMID: 37114235 Free PMC article.
References
-
- Mealy MA, Wingerchuk DM, Greenberg BM, Levy M. Epidemiology of neuromyelitis optica in the United States: a multicenter analysis. Arch Neurol. 2012;69(9):1176–1180. - PubMed
-
- Pereira WL, Reiche EM, Kallaur AP, Kaimen-Maciel DR. Epidemiological, clinical, and immunological characteristics of neuromyelitis optica: a review. J Neurol Sci. 2015;355(1–2):7–17. - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources